



Abivax announces the resumption of its liquidity contract

November 21, 2023

Paris, France, November 21, 2023 – 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“**Abivax**” or the “**Company**”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces the resumption, as of today, of its liquidity contract and the end of the stabilization period.

The liquidity contract was entered into with TSAF on June 26, 2015, and suspended in the context of the initial public offering of Abivax shares in the form of ADS on the Nasdaq Global Market. Following the stabilization activities carried out since October 20, 2023, the stabilization period has ended on November 20, 2023. The underwriters have not exercised the overallotment option.

As of November 20, 2023, the following means are allocated to the liquidity account for the execution of this contract:

- 11,257 Abivax shares held on behalf of Abivax,
- €315,223.32.

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S., Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on X, formerly Twitter, @ABIVAX.

Contacts

Abivax Communications

Abivax Investor Relations

Regina Jehle

Patrick Malloy

regina.jehle@abivax.com

patrick.malloy@abivax.com

+33 6 24 60 69 63

+1 847 987 4878

Disclaimers

This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares or ADSs in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

This press release has been prepared in both French and English. In the event of any differences between the two versions of the press release, the French language version shall supersede.

European Economic Area

In relation to each Member State of the European Economic Area (each, a “**Relevant State**”), no offer to the public of ordinary shares and ADSs may be made in that Relevant State other than:

- to any legal entity which is a qualified investor as defined under Article 2(e) of the Prospectus Regulation;
- to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or
- in any other circumstances falling within Article 1(4) of the Prospectus Regulation,

provided that no such offer of the securities shall require the Company or any of its representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus

Regulation.

For the purposes of this provision, the expression an “offer to the public” in relation to the securities in any Relevant State means the communication in any form and by any means presenting sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities, and the expression “**Prospectus Regulation**” means Regulation (EU) 2017/1129 of June 14, 2017, as amended.

France

The securities have not been and will not be offered or sold to the public in the Republic of France, and no offering of this prospectus or any marketing materials relating to securities may be made available or distributed in any way that would constitute, directly or indirectly, an offer to the public in the Republic of France (except for public offerings defined in Article L.411-2 1° of the French Monetary and Financial Code (*Code monétaire et financier*)).

The securities may only be offered or sold in France pursuant to Article L. 411-2 1° of the French Monetary and Financial Code (*Code monétaire et financier*) to qualified investors (*investisseurs qualifiés*) (as such term is defined in Article 2(e) of the Prospectus Regulation) acting for their own account, and in accordance with Articles L. 411-1, L. 411-2 and D. 411-2 to D.411-4 of the French Monetary and Financial Code (*Code monétaire et financier*).

This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.